Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Share Finance Facility

15 Sep 2005 08:00

ReGen Therapeutics PLC15 September 2005 ReGen Therapeutics Plc Date 15 September 2005 Committed Share Finance Facility ReGen Therapeutics Plc ("ReGen" or the "Company") announces that on 14thSeptember 2005 it entered into an agreement with the Headstart Group of funds ("Headstart") under which Headstart will make available to the Company acommitted share finance facility of up to £2,000,000 (the "Headstart Facility"). Pursuant to the terms of the Headstart Facility, Headstart has agreed, whencalled upon by the Company, to subscribe for, or purchase, new ordinary sharesin the capital of the Company ("Ordinary Shares") to the value of up to, inaggregate, £2,000,000. The Headstart Facility is available at any time up to 3years from the date a Committed Share Finance Facility Agreement is entered intoby the Company and Headstart and can be drawn down by the Company in incrementsof up to £50,000. The subscription price for an Ordinary Share shall be equalto 95% of the lowest closing bid price of an Ordinary Share in the fifteentrading days following the date on which the Company notifies Headstart that itwishes to make a draw down under the Headstart Facility. In consideration for Headstart making available the Headstart Facility, theCompany has agreed to pay Headstart a one-off underwriting commission of £60,000payable by the issue of Ordinary Shares (on the basis of an agreed value perOrdinary Share of 1.35p, being the closing bid price on Wednesday 7th September2005). £30,000 of the underwriting commission was payable upon entering into theHeadstart Facility and the remaining £30,000 is payable on the first anniversarythereafter. Accordingly, application has been made for 2,222,222 OrdinaryShares to be admitted to trading on the AIM market. It is expected thatadmission to listing will become effective and that dealings in these shareswill commence on Tuesday 20th September 2005. In addition, the Company hasagreed, subject to shareholder approval, to issue warrants granting Headstartthe right to subscribe for up to 4,000,000 Ordinary Shares at a subscriptionprice of 1.65p per share, being a price equal to 110% of the closing bid priceof the Company's shares on 13th September 2005. Such warrants will beexercisable at any time on or before 14th September 2008. As the issue of theWarrants is subject to shareholder approval, ReGen will shortly send toshareholders a circular containing a notice convening an extraordinary generalmeeting of the Company (the "Circular") for 10.00 a.m. on 10 October 2005 (the "EGM") containing resolutions to, inter alia, approve the issue of the Warrants. Copies of the Circular will be available, for collection only, free of charge tothe public, from the Company, Suite 406, Langham House, 29-30 Margaret Street,London W1W 8SA during normal office hours on any day (Saturdays, Sundaysexcepted) from 19 September 2005 until 14 October 2005. - For further information, please contact:Andrew MarshallMarshall Robinson RoeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Apr 20097:00 amRNSIssue of Equity
31st Mar 200910:49 amRNSTotal Voting Rights
26th Mar 20095:38 pmRNSNotification of Major Interest in Shares
26th Mar 200912:49 pmRNSResults of General Meeting
25th Mar 20099:30 amRNSNotification of Major Interest in Shares
25th Mar 20097:00 amRNSDistribution Agreement and Issue of Equity
25th Mar 20097:00 amRNSManufacturing Agreement
12th Mar 20097:00 amRNSFirst stage peptide studies
4th Mar 20094:07 pmRNSHolding(s) in Company
2nd Mar 20097:00 amRNSEGM Circular
27th Feb 20093:09 pmRNSTotal Voting Rights
26th Feb 20097:00 amRNSHoldings in Company
19th Feb 20097:00 amRNSFurther issue of shares
18th Feb 20097:00 amRNSIssue of Equity and Shareholdings
30th Jan 200912:53 pmRNSTotal Voting Rights
26th Jan 200912:21 pmRNSDistribution agreement in Turkey
20th Jan 20095:03 pmRNSHolding(s) in Company
15th Jan 20091:43 pmRNSIssue of Equity
6th Jan 20093:23 pmRNSResults of General Meeting
5th Jan 20094:41 pmRNSIssue of Equity
31st Dec 20087:00 amRNSTotal Voting Rights
19th Dec 20084:22 pmRNSHolding(s) in Company
12th Dec 200810:47 amRNSNotice of EGM
9th Dec 20084:30 pmRNSIssue of Equity
8th Dec 200811:15 amRNSA Book on Zolpidem Effects Published
4th Dec 200810:13 amRNSFull Colostrinin Study Results published
28th Nov 20084:24 pmRNSTotal Voting Rights
26th Nov 20087:00 amRNSColostrinin Test marketing in Poland
25th Nov 20083:39 pmRNSIssue of Equity
24th Nov 20087:00 amRNSFocus on Colostrinin revenue generation
10th Nov 20087:00 amRNSIssue of Shares
4th Nov 20081:10 pmRNSShareholding
31st Oct 200810:56 amRNSTotal Voting Rights
27th Oct 20087:00 amRNSIssue of Equity
13th Oct 20085:19 pmRNSSignificant Shareholding
9th Oct 20083:59 pmRNSHolding(s) in Company
9th Oct 20087:00 amRNSEuropean Launch of Colostrinin in Cyprus
6th Oct 200812:51 pmRNSGeneral Meeting, Share Capital Sub-division
6th Oct 20087:00 amRNSZolpidem Review
2nd Oct 20082:03 pmRNSSignificant Shareholding
30th Sep 20083:44 pmRNSTotal Voting Rights
23rd Sep 20085:29 pmRNSHolding(s) in Company
23rd Sep 20085:21 pmRNSHolding(s) in Company
23rd Sep 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSIssue of Equity
12th Sep 20087:00 amRNSGeneral Meeting
2nd Sep 20084:07 pmRNSTR-1 announcement
29th Aug 200812:33 pmRNSTotal Voting Rights
13th Aug 20087:00 amRNSPlacing
12th Aug 20087:00 amRNSFinancing and Commercial Upda

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.